Suchergebnisse - "EIGER DANIEL"

PubPharm (34)

1

The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer : a sub-analysis of the ALTTO study

enthalten in: Breast cancer research and treatment | 2024

von Martins-Branco, D. | Kassapian, M. | Debien, V. | +14

2

Author Correction : Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

enthalten in: Nature communications | 2023

von Buisseret, L. | Loirat, D. | Aftimos, P. | +33

ErratumFor: Nat Commun. 2023 Nov 2;14(1):7018. - PMID 37919269

3

The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study

enthalten in: Breast cancer research and treatment | 2023

von Martins-Branco, D. | Kassapian, M. | Debien, V. | +14

4

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer : the randomized SYNERGY phase I/II trial

enthalten in: Nature communications | 2023

von Buisseret, L. | Loirat, D. | Aftimos, P. | +33

ErratumIn: Nat Commun. 2023 Dec 12;14(1):8223. - PMID 38086864

5

COMBINATION THERAPIES FOR BREAST CANCER

enthalten in: Europäisches Patentamt | 2023

von EIGER DANIEL | HAFNER MARC ANTOINE | HEESON SARAH LOUISE | +6

6

COMBINATION THERAPIES FOR BREAST CANCER

enthalten in: Europäisches Patentamt | 2023

von EIGER DANIEL | HAFNER MARC ANTOINE | HEESON SARAH LOUISE | +6

7

Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study

enthalten in: British journal of cancer | 2022

von Nader-Marta, G. | Debien, V. | Eiger, D. | +16

8

Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer : Primary Results of the Randomized Phase III IMpassion050 Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Huober, J. | Barrios, C. | Niikura, N. | +13

9

BERENICE Final Analysis : Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer

enthalten in: Cancers | 2022

von Dang, C. | Ewer, M. | Delaloge, S. | +11

10

Timelines to initiate a phase III trial across the globe : a sub-analysis of the APHINITY trial

enthalten in: Ecancermedicalscience | 2022

von Franzoi, M. | Procter, M. | Twelves, C. | +9